- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00031954
Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
A Phase II Study Of Paclitaxel, Carboplatin And Gemcitabine In Previously Untreated Patients With Epithelial Ovarian Carcinoma FIGO Stage IIB-IV
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have stage IC, stage IIB, stage III, or stage IV ovarian epithelial, fallopian tube, or peritoneal cancer that has not been previously treated.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
OBJECTIVES:
- Determine the tolerability and toxicity of paclitaxel, carboplatin, and gemcitabine in patients with previously untreated stage IC-IV ovarian epithelial, fallopian tube, or peritoneal carcinoma.
- Determine the response rate of patients treated with this regimen.
- Determine the time to progression and overall survival of patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and gemcitabine IV over 30-60 minutes on days 1 and 8. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed at 3 and 6 months.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Berlin, Tyskland, D-10117
- Universitaetsklinikum Charite
-
Bremen, Tyskland, D-28205
- Zentralkrankenhaus
-
Dresden, Tyskland, D-01307
- Medizinische Klinik I
-
Dusseldorf, Tyskland, DOH-4-0217
- Evangelisches Krankenhaus
-
Frankfurt, Tyskland, D-60590
- Klinikum der J.W. Goethe Universitaet
-
Frankfurt Am Main, Tyskland, 65929
- Staedtisches Krankenhaus FFM-Hoechst
-
Gottingen, Tyskland, D-37075
- Universitaetsklinik Goettingen
-
Greifswald, Tyskland, D-17487
- Klinik Fuer Innere Medizin Hematology/Oncology, Ernst Moritz Armdt Universitaet
-
Hannover, Tyskland, 30659
- Frauenklinik der MHH
-
Karlsruhe, Tyskland, D-76137
- Vincentius Krankenhaus
-
Kiel, Tyskland, D-24105
- Christian-Albrechts University of Kiel
-
Magdeburg, Tyskland, 39108
- Klinik der Otto-v.-Guericke-Universitat
-
Muenster, Tyskland, D-48129
- Klinik und Poliklinik fuer Kinderheilkunde
-
Munich (Muenchen), Tyskland, D-81377
- Klinikum Großhadern
-
Munich (Muenchen), Tyskland, D-81675
- Klinikum Rechts Der Isar/Technische Universitaet Muenchen
-
Tuebingen, Tyskland, D-72076
- Universitaetsklinikum Tuebingen
-
Ulm, Tyskland, D-89075
- Universitaet Ulm
-
Wiesbaden, Tyskland, D-65199
- Dr. Horst-Schmidt-Kliniken
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS:
Histologically confirmed stage IC-IV ovarian epithelial, fallopian tube, or peritoneal carcinoma
- No tumors of low-malignant potential (borderline tumors)
- No symptomatic brain metastases
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- ECOG 0-2 OR
- Karnofsky 70-100%
Life expectancy:
- At least 6 months
Hematopoietic:
- WBC at least 3,000/mm^3
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin greater than 10 g/dL
Hepatic:
- Bilirubin no greater than 2 times upper limit of normal
Renal:
- Glomerular filtration rate at least 60 mL/min
Cardiovascular:
- No history of congestive heart failure (New York Heart Association class III or IV heart disease) even if medically controlled
- No myocardial infarction within the past 6 months
- No history of atrial or ventricular arrhythmias
Neurologic:
- No history of seizure disorder
- No history of CNS disorder
- No pre-existing motor or sensory neuropathy or symptoms grade 2 or greater
Other:
- No severe concurrent infection
- No prior hypersensitivity reaction to products containing Cremophor EL or compounds chemically related to carboplatin, paclitaxel, or gemcitabine
- No complete bowel obstruction
- No other concurrent severe medical problems that would preclude study
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No concurrent immunotherapy
- No concurrent WBC transfusions
Chemotherapy:
- No prior chemotherapy
- No other concurrent chemotherapy
Endocrine therapy:
- No concurrent hormonal therapy except replacement therapy or steroid antiemetics
Radiotherapy:
- No prior radiotherapy
- No concurrent radiotherapy
Surgery:
- No more than 6 weeks since prior definitive surgery
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Evaluation of tolerability and toxicity of the combination therapy with paclitaxel, carboplatin and gemcitabine (P-C-G) in first line treatment of ovarian cancer patients. Evaluation of Drop-out rate due to toxicity
Tidsramme: Based on decision level
|
The decision level is reached, when the lower exact 95% confidence limit of the observed proportion is higher than the upper exact 95% confidence limit of the historical proportion, which corresponds to a power of 0.5 applying a significance level of 0.05
|
Based on decision level
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neoplasmer
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Genitale neoplasmer, kvindelige
- Adnexale sygdomme
- Æggeledersygdomme
- Æggelederneoplasmer
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Enzymhæmmere
- Antimetabolitter, Antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Tubulin modulatorer
- Antimitotiske midler
- Mitose modulatorer
- Antineoplastiske midler, fytogene
- Gemcitabin
- Carboplatin
- Paclitaxel
Andre undersøgelses-id-numre
- AGO-OVAR 8
- AGOSG-OVAR-8
- EU-20146
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med carboplatin
-
Eisai Inc.AfsluttetKræftForenede Stater, Østrig, Indien
-
Samyang Biopharmaceuticals CorporationAfsluttet
-
NHS Greater Glasgow and ClydeAfsluttetLivmoderhalskræft | Æggelederkræft | Primær peritoneal kræftDet Forenede Kongerige, Australien, New Zealand
-
Duke UniversityAfsluttetTumorer i hjernen og centralnervesystemetForenede Stater, Canada
-
National Cancer Institute (NCI)Children's Oncology GroupAfsluttetTumorer i hjernen og centralnervesystemetForenede Stater, Canada, Puerto Rico, Australien, Holland, New Zealand, Schweiz
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUkendtIntraokulært retinoblastomIndien
-
National Cancer Institute (NCI)AfsluttetBrystkræft | LivmoderhalskræftForenede Stater
-
Medical Research CouncilEuropean Organisation for Research and Treatment of Cancer - EORTCAfsluttetTestikulær kimcelletumorDet Forenede Kongerige, Canada, Norge, Holland, Sydafrika, Brasilien, Finland
-
AkesoRekrutteringAvanceret pladeepitel, ikke-småcellet lungekræftKina
-
Rennes University HospitalAfsluttetLivmoderhalskræftFrankrig